FDA investigators have not spoken with patients and others alleging misconduct in MDMA trials

Taking stock of the drug industry, from the lab to the medicine chest

July 19, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Multidisciplinary Association for Psychedelic Studies STAT+ | FDA investigators have not spoken with patients and others alleging misconduct in MDMA trials The FDA said it's investigating Lykos studies of MDMA treatment for PTSD. Key people involved in misconduct claims have yet to be contacted. By Olivia Goldhill Massive study of veterans' DNA shows how diversity can help researchers decipher the genome Inclusion of non-Europeans improved ability to pinpoint genetic variants that raise health risks. Study "sets a new bar" in genomic analysis. By Jonathan Wosen Listen: JD Vance's biotech ties, Cassava resignations, and insulin shortages Sarah Owermohle joins the podcast to talk about how JD Vance could influence health policy if Trump wins the election. By Elaine Chen, Allison DeAngelis, and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser